JP2022502432A5 - - Google Patents
Info
- Publication number
- JP2022502432A5 JP2022502432A5 JP2021517294A JP2021517294A JP2022502432A5 JP 2022502432 A5 JP2022502432 A5 JP 2022502432A5 JP 2021517294 A JP2021517294 A JP 2021517294A JP 2021517294 A JP2021517294 A JP 2021517294A JP 2022502432 A5 JP2022502432 A5 JP 2022502432A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- approximately
- glp
- analog
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024120747A JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18197755.4 | 2018-09-28 | ||
| EP18197755.4A EP3628683A1 (en) | 2018-09-28 | 2018-09-28 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
| PCT/EP2019/076305 WO2020065064A1 (en) | 2018-09-28 | 2019-09-27 | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120747A Division JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502432A JP2022502432A (ja) | 2022-01-11 |
| JP2022502432A5 true JP2022502432A5 (https=) | 2022-09-13 |
| JP7566730B2 JP7566730B2 (ja) | 2024-10-15 |
Family
ID=63794308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517294A Active JP7566730B2 (ja) | 2018-09-28 | 2019-09-27 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
| JP2024120747A Active JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120747A Active JP7738136B2 (ja) | 2018-09-28 | 2024-07-26 | グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220265551A1 (https=) |
| EP (2) | EP3628683A1 (https=) |
| JP (2) | JP7566730B2 (https=) |
| KR (2) | KR20260008798A (https=) |
| CN (3) | CN112771073B (https=) |
| AU (1) | AU2019348538B2 (https=) |
| BR (1) | BR112021005858A2 (https=) |
| CA (1) | CA3114330A1 (https=) |
| CL (1) | CL2021000678A1 (https=) |
| IL (1) | IL281362B1 (https=) |
| MX (2) | MX2021003271A (https=) |
| NZ (1) | NZ775113A (https=) |
| SG (1) | SG11202102383VA (https=) |
| WO (1) | WO2020065064A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299864B2 (en) | 2017-06-16 | 2024-06-01 | Zealand Pharma As | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| MX2022014671A (es) * | 2020-05-22 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de conjugado de glp-2 de accion prolongada. |
| MX2023006901A (es) * | 2020-12-16 | 2023-06-26 | Zealand Pharma As | Uso de analogos de glp-2 en pacientes con insuficiencia renal. |
| RS67423B1 (sr) * | 2021-09-10 | 2025-12-31 | Zealand Pharma As | Postupak za formulisanje sastava koji sadrže analoge glukagonu sličnog peptida-2 (glp-2) |
| IL313732A (en) | 2021-12-23 | 2024-08-01 | Zealand Pharma As | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
| KR20250075601A (ko) | 2022-09-30 | 2025-05-28 | 질랜드 파마 에이/에스 | 글루카곤-유사-펩타이드-2(glp-2) 유사체 및 단장 증후군(sbs) 치료를 위한 이의 의학적 용도 |
| US20240415933A1 (en) * | 2022-10-03 | 2024-12-19 | Orbicular Pharmaceutical Technologies Private Limited | Stable injectable compositions of glp-2 peptide |
| IL322328A (en) | 2023-01-27 | 2025-09-01 | Zealand Pharma As | Glucagon-like peptide-2 (GLP-2) analogs and their medical uses for the treatment of short bowel syndrome (SBS) |
| TW202535919A (zh) | 2023-12-28 | 2025-09-16 | 丹麥商西蘭製藥公司 | 類升糖素肽2(glp-2)類似物之調配物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225496B1 (en) * | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| EP1231219B1 (en) | 1996-04-12 | 2010-08-25 | 1149336 Ontario Inc. | GLucagon-like peptide-2 analogs |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU2020501A (en) | 1999-12-08 | 2001-06-18 | 1149336 Ontario Inc. | Chemotherapy treatment |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DK1360202T3 (da) | 2001-02-16 | 2008-09-22 | Conjuchem Biotechnologies Inc | Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser |
| ES2336826T3 (es) * | 2005-05-03 | 2010-04-16 | Novetide, Ltd. | Procedimientos para la produccion de un peptido que presenta una amida c-terminal. |
| UA95235C2 (en) * | 2005-05-04 | 2011-07-25 | Зииланд Фарма А/С | Glucagon-like-peptide-2 (glp-2) analogues |
| CN101341254A (zh) * | 2005-12-24 | 2009-01-07 | 蒂加斯克乳制品研究中心 | 反-10，顺-12十八碳二烯酸的生产方法 |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| CN101573376B (zh) * | 2006-11-08 | 2013-11-06 | 西兰制药公司 | 选择性胰高血糖素样肽-2（glp-2）类似物 |
| CN101668535B (zh) * | 2006-12-29 | 2017-07-28 | 益普生制药股份有限公司 | Glp‑1药物组合物 |
| KR20130115086A (ko) * | 2010-05-17 | 2013-10-21 | 세빅스 인코포레이티드 | 페길화된 c-펩티드 |
| FR2994390B1 (fr) * | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| HRP20161703T1 (hr) * | 2012-11-20 | 2017-03-10 | Fresenius Kabi Usa, Llc | Formulacije kaspofungin acetata |
| WO2016065181A1 (en) * | 2014-10-23 | 2016-04-28 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| LT3541366T (lt) * | 2016-11-21 | 2025-03-10 | Amylyx Pharmaceuticals, Inc. | Eksendino (9-39) buferiniai preparatai |
-
2018
- 2018-09-28 EP EP18197755.4A patent/EP3628683A1/en not_active Withdrawn
-
2019
- 2019-09-27 JP JP2021517294A patent/JP7566730B2/ja active Active
- 2019-09-27 MX MX2021003271A patent/MX2021003271A/es unknown
- 2019-09-27 CA CA3114330A patent/CA3114330A1/en active Pending
- 2019-09-27 US US17/276,252 patent/US20220265551A1/en active Pending
- 2019-09-27 WO PCT/EP2019/076305 patent/WO2020065064A1/en not_active Ceased
- 2019-09-27 CN CN201980063594.1A patent/CN112771073B/zh active Active
- 2019-09-27 SG SG11202102383VA patent/SG11202102383VA/en unknown
- 2019-09-27 NZ NZ775113A patent/NZ775113A/en unknown
- 2019-09-27 EP EP19773860.2A patent/EP3856766A1/en active Pending
- 2019-09-27 BR BR112021005858-3A patent/BR112021005858A2/pt unknown
- 2019-09-27 KR KR1020257041229A patent/KR20260008798A/ko active Pending
- 2019-09-27 CN CN202510255078.6A patent/CN120204366A/zh active Pending
- 2019-09-27 AU AU2019348538A patent/AU2019348538B2/en active Active
- 2019-09-27 CN CN202410277209.6A patent/CN118267455A/zh active Pending
- 2019-09-27 KR KR1020217010775A patent/KR20210069056A/ko not_active Ceased
-
2021
- 2021-03-09 IL IL281362A patent/IL281362B1/en unknown
- 2021-03-19 CL CL2021000678A patent/CL2021000678A1/es unknown
- 2021-03-19 MX MX2026000859A patent/MX2026000859A/es unknown
-
2023
- 2023-10-16 US US18/487,666 patent/US20240065978A1/en active Pending
-
2024
- 2024-07-26 JP JP2024120747A patent/JP7738136B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502432A5 (https=) | ||
| US10485851B2 (en) | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | |
| ES2320754T3 (es) | Tratamiento de la diabetes. | |
| JP6111475B2 (ja) | ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物 | |
| KR20250090374A (ko) | Gip/glp1 작용제 조성물 | |
| HK1248607A1 (zh) | Ph为7且至少含pi为5．8至8．5之基础胰岛素和取代共聚(氨基酸)的可注射溶液 | |
| AU2019348538B2 (en) | Formulations of glucagon-like-peptide-2 (GLP-2) analogues | |
| TW201938189A (zh) | 包含至少一具有pi從5.8至8.5之基礎胰島素以及一帶有羧酸鹽電荷及疏水基之共聚胺基酸的可注射ph7溶液 | |
| JP2014524480A5 (https=) | ||
| JP2025020319A (ja) | テルリプレシン組成物およびその使用方法 | |
| JP2008521840A5 (https=) | ||
| WO2009068708A2 (es) | Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo | |
| CN110087666A (zh) | 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法 | |
| JP2022522833A (ja) | １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形 | |
| CN107661288A (zh) | 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备 | |
| EP3856767B1 (en) | Formulations of glucagon-like-peptide-2 (glp-2) analogues | |
| JP2021519321A5 (https=) | ||
| EP2604264B1 (en) | Pharmaceutical composition for treating viral diseases | |
| US11963940B2 (en) | Parenteral esmolol formulation | |
| TW201815410A (zh) | 藥物之經黏膜吸收促進劑 | |
| RU2021106892A (ru) | Составы аналогов глюкагоноподобного пептида-2 (glp-2) | |
| RS67423B1 (sr) | Postupak za formulisanje sastava koji sadrže analoge glukagonu sličnog peptida-2 (glp-2) | |
| JP3022915B2 (ja) | 癌転移抑制剤 | |
| RU2833459C2 (ru) | Составы аналогов глюкагоноподобного пептида-2 (glp-2) | |
| CA3041362C (en) | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia |